中信证券研报表示,行业增长有所放缓,头部药店发展空间显著。扩张成本有所增加,商品结构持续分化。改革进入深水区,行业合规化进程加速。上市公司专注提质增效,行业新业态值得期待。维持连锁药店“强于大市”评级。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.